MDB Capital (NASDAQ:MDBH) Trading Down 0.4% – What’s Next?

MDB Capital Holdings, LLC (NASDAQ:MDBH) fell 0.4% during trading on Thursday . The company traded as low as $3.32 and last traded at $3.3850. 2,874 shares changed hands during trading, a decline of 30% from the average session volume of 4,122 shares. The stock had previously closed at $3.40.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDB Capital in a research report on Thursday, July 2nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

MDB Capital Stock Performance

The company has a market capitalization of $34.39 million, a PE ratio of -1.57 and a beta of 1.17. The company’s 50-day simple moving average is $3.34 and its 200-day simple moving average is $3.31.

MDB Capital (NASDAQ:MDBH) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.65) EPS for the quarter.

Institutional Trading of MDB Capital

A number of hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new position in shares of MDB Capital during the 2nd quarter valued at about $27,000. DRW Securities LLC acquired a new stake in shares of MDB Capital during the fourth quarter worth approximately $40,000. Finally, Citadel Advisors LLC bought a new stake in MDB Capital during the 3rd quarter worth about $43,000. 0.35% of the stock is owned by hedge funds and other institutional investors.

About MDB Capital

MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business.